Project Grant HT94252510791
- The U.S. Defense Health Agency awarded a $1,751,468.00 Project Grant to the Weill Medical College of Cornell University on September 1, 2025 through the Military Medical Research and Development program (CFDA 12.420). The grant supports advanced biomedical research to investigate the "circulating antibody repertoire and blood-brain-barrier impairment" that may explain neuropsychiatric symptoms associated with "invisible" brain injuries. As a prestigious academic medical...
- The U.S. Defense Health Agency awarded a $808,141 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Weill Medical College of Cornell University. The grant is titled "Targeting Inflammatory Pathways in Breast Cancer Brain Metastases for the Treatment of Edema and Radiation Necrosis Using Anti-VEGF Ultrasmall Particle Therapy". The grant period is from February 1, 2025 to January 31, 2027. The funding supports advanced biomedical research aimed at...
- The federal Project Grant award of $1,685,582.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to Weill Medical College of Cornell University supports "Theranostic TROP-2-Directed Pretargeted Radioimmunotherapy for Metastatic" research. This project aims to advance innovative medical solutions for treating cancer, with a focus on developing theranostic radioimmunotherapy approaches targeting the TROP-2 protein. The grant, with a...
- The U.S. Defense Health Agency awarded a $762,750 Project Grant to the Weill Medical College of Cornell University on May 1, 2025 under the Military Medical Research and Development program (CFDA 12.420). The grant supports a 3-year research project titled "Nutrition-Based Programming of Dendritic Cells for Ovarian Cancer Immunotherapy", with a planned completion date of April 30, 2028. Through this award, the Weill Medical College will conduct advanced biomedical research to...
- This $988,740 Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Weill Medical College of Cornell University to investigate "Genomically Informed Morphological Stromal Signatures to Predict Lethal Prostate Cancer". The 3-year research project, running from June 2025 to June 2028, aims to advance the understanding of prostate cancer biology and develop new predictive biomarkers to...
- The Department of the Army Medical Command awarded a $762,750 Project Grant to Weill Medical College of Cornell University under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research on perk-driven stress responses that regulate dendritic cell function in ovarian cancer. Through June 2024, Weill Medical College will investigate how stress responses impact immune cell activity and how this relationship influences ovarian cancer progression....
- This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research aimed at "RESTORATION OF CLEAR CELL RENAL CELL CARCINOMA TUMORIGENICITY BY CELL REPROGRAMMING". The $1,356,000.00 award was granted to Weill Medical College of Cornell University and has a performance period from November 1, 2024 to October 31, 2028. This award is part of the Defense Health Agency's efforts to transform...
- The Defense Health Agency awarded a $7,694,338 Project Grant on September 30, 2025 to the Icahn School of Medicine at Mount Sinai under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "LIVING WITH VIOLENCE-RELATED BRAIN INJURY: OPTIMIZING COGNITIVE AND PSYCHOLOGICAL WELLNESS THROUGH THE LIVEWELL BRAIN HEALTH STUDY," supports advanced biomedical research to transform healthcare for military service members, veterans, and the public through...
- The Defense Health Agency awarded a $2,542,500 Project Grant to the Weill Medical College of Cornell University for the project "THERAPEUTIC TARGETING OF THE TUMOR MICROENVIRONMENT IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS AT HIGH RISK OF RELAPSE AND PRECLINICAL MODELS OF LUNG METASTASES". The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military personnel,...
- The federal Project Grant award of $669,400.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program to Weill Medical College of Cornell University. The award is for a project titled "INVESTIGATING THE BIOLOGICAL MECHANISMS AND THERAPEUTIC RELEVANCE OF THE SLC1A1 AMINO ACID TRANSPORTER IN KIDNEY CANCER" with a performance period from September 1, 2025 to August 31, 2029. The project aims to advance biomedical...
This federal Project Grant award of $553,189.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by Weill Medical College of Cornell University. The research aims to investigate the circulating antibody repertoire and blood-brain-barrier impairment as potential explanations for the neuropsychiatric symptoms associated with "invisible" brain injuries. The award period runs from September 1, 2025 to August 31, 2029. As a prestigious academic medical institution, Weill Medical College has extensive experience delivering specialized biomedical research and development services for various federal agencies, particularly in areas like cancer research, neuroscience, and translational science.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $553.2k | 8/14/25 |